BioCentury
ARTICLE | Clinical News

BAX 817: Phase III data

March 23, 2015 7:00 AM UTC

An open-label, international Phase III trial in about 40 male patients ages 12-65 with hemophilia A or B with inhibitors showed that on-demand treatment with 3 IV injections of 90 ug/kg BAX 817 and 1 ...